Patient Safety Merits New Review for Modified Medical Devices

The U.S. Food and Drug Administration (FDA) should require clinical data to be submitted as part of a more rigorous re-evaluation of medical devices that are modified after approval for patient safety.

The U.S. Food and Drug Administration (FDA) should require clinical data to be submitted as part of a more rigorous re-evaluation of medical devices that are modified after approval for patient safety.

This is according to UC San Francisco physician scientists in a commentary published online March 24, 2014 in the Annals of Internal Medicine. According to authors Rita Redberg, MD, UCSF professor of medicine, and UCSF second-year medical student Sarah Zheng, such a requirement could prevent deaths due to insufficiently tested device modifications.

Top Cardiac Surgeon and Team Perform 12 Bypass Surgeries on a Single Patient
One of India’s leading cardiac surgeons Ramakant Panda performed a complex surgery on a 58-year old man.

"The need for rapid approval of design improvements to marketed devices must be weighed against the possibility of introducing unknown risks to patient health from such modifications," the authors wrote in their commentary.

In addition, Redberg said, "A requirement that post-marketing clinical data, including adverse events, be collected and deposited into a public data base would allow for the best identification of patients who could benefit from a device, without slowing market entry."

The growing medical device industry is expected to generate $228 billion in sales by 2015 for technologies ranging from orthopedic knee replacements to cochlear implants, to infusion pumps. Many devices are invasively installed within the body, and the potential complications when they fail can be great.

Patient Epigenetic Machinery Hijacked by Some Breast Cancer Cells to Evade Drug Therapy
Study says breast cancer therapy that blocks estrogen synthesis sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms.

Examples of avoidable outcomes, according to Redberg and Zheng, include hundreds of failures and five deaths arising from use of the modified Sprint Fidelis defibrillator electrical lead wire made by Medtronic, Inc., prompting a recall, and a similar recall of defibrillator leads marketed by St. Jude Medical, Inc., after 227,000 had been implanted in patients.

The FDA evaluates safety and effectiveness of new, high-risk medical devices before they are marketed, through a process known as premarket approval (PMA). This procedure involves the submission and review of clinical-trials data. However, modifications of existing devices may be approved without additional clinical data, through a less rigorous procedure called a PMA supplement.

Guide Protocol for Stroke Patients
Neurologists have debated as how to help prevent stroke patients from suffering a second stroke.

"Companies often submit changes to a device one supplement at a time instead of submitting multiple changes in a single application," Redberg and Zheng stated in the commentary. "As a result, each submitted modification is evaluated separately, a process that makes it difficult, if not impossible, to take into account the cumulative effects and interactions of multiple modifications."

The Medtronic and St. Jude Medical devices were modified multiple times through PMA supplements without additional clinical data submission, the authors noted.

Doctors Record 'Higher' Blood Pressure in Patients
A new data has revealed how doctors record blood pressure levels that are higher than those recorded by nurses

Clinicians may favor use of a device based on original research on a much earlier version, with no knowledge of substantial, untested modifications that have been made to the currently available device, they said.

The authors advocated for clear labeling of devices to highlight modifications to physicians and alert them to unevaluated risks.

Source-Eurekalert